Amgen Inc. $AMGN Shares Purchased by First Trust Advisors LP

First Trust Advisors LP grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 32.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 640,120 shares of the medical research company’s stock after buying an additional 155,930 shares during the period. First Trust Advisors LP’s holdings in Amgen were worth $225,226,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. raised its holdings in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new stake in Amgen during the 4th quarter worth approximately $1,669,000. Adell Harriman & Carpenter Inc. raised its holdings in Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after buying an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Amgen during the fourth quarter valued at approximately $22,441,000. Finally, Robinhood Asset Management LLC acquired a new position in Amgen during the fourth quarter valued at approximately $17,526,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group began coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 target price on the stock. Argus decreased their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Truist Financial raised their price objective on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $356.62.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $366.05 on Thursday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company’s fifty day moving average price is $349.58 and its two-hundred day moving average price is $351.32. The firm has a market capitalization of $197.56 billion, a P/E ratio of 25.47, a P/E/G ratio of 3.71 and a beta of 0.41. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the firm earned $4.90 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.